PatientsVille.com Logo

Psychotic and Risperdal

PatientsVille

Psychotic Symptoms and Causes

Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there.

Schizophrenia is one type of Psychotic disorder. People with bipolar disorder may also have Psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke.

Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

Check out the latest treatments for psychotic

psychotic treatment research studies

Risperdal clinical trials, surveys and public health registries


Find Drug Side Effect reports



Risperdal Side Effects

Weight Increased (453)
Suicide Attempt (403)
Diabetes Mellitus (381)
Self Injurious Behaviour (331)
Intentional Overdose (330)
Somnolence (292)
Aggression (259)
Death (250)
Overdose (223)
Tachycardia (218)
Fall (214)
Fatigue (187)
Neuroleptic Malignant Syndrome (183)
Psychotic Disorder (182)
Off Label Use (181)
Agitation (180)
Anxiety (178)
Suicidal Ideation (177)
Depression (173)
Abnormal Behaviour (171)
Extrapyramidal Disorder (170)
Insomnia (169)
Hospitalisation (169)
Convulsion (169)
Tremor (166)
Confusional State (158)
Dizziness (156)
Blood Prolactin Increased (156)
Leukopenia (154)
Tardive Dyskinesia (150)
Type 2 Diabetes Mellitus (144)
Treatment Noncompliance (144)
Pneumonia (143)
Hypotension (135)
Weight Decreased (127)
Hallucination (127)
Blood Creatine Phosphokinase Increased (126)
Pyrexia (125)
Myocardial Infarction (123)
Completed Suicide (123)
Dyspnoea (123)
Vomiting (122)
Hyponatraemia (122)
Dyskinesia (121)
Sedation (120)
Akathisia (120)
Asthenia (120)
Headache (117)
Gait Disturbance (117)
Dysphagia (116)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Do you think i have a Psychotic disorder

I experienced a near death medical event (PE) and began acting without any care about my own health by seeking and attaing a full-time job without declaring my illness less than a month after leaving hospital, I left the job due to heart pains within

I have a neurological condition of grand mal epilepsy and when i have an attack which is usually 7-8 attacks one after another. When am not aware an ambulance staff have attended to me i get wild with all the staff and throw punches but am not aware

I think so altho am not sure for definite because i started getting these conditions i have since i left secondary school and have had jobs before and have lost it within two months. I have had a number of jobs and have been wrongfully dismissed u

Is it ok to take Valerian with Risperadal (I take 1.5 mg a day)?

Janet. I suffer from/dx psychotic depression and experience psychotic episodes 2 - 3x a month. I was able to hold a job for 25 yrs before it got really bad. My episodes are delusional. From the little info you provided, I dont see any of the hallmar

Went from 96 lbs to 170 lbs in a few short months. Haven't been able to lose any of the weight. I no longer have periods either. Haven't had one since 08. I'm writing this comment in May of 2010. Besi

What kind of antipsychotics cause less side effect of increased prolactin??

<span style='color: #808080;'><b>Describe Your Schizophrenia from HPV (GARDASIL) 2007 Experience Here:My 15 year old sonjust received first vaccination for HPV, nine days later experienced a psychotic disorder for one week, now

9 yr old son put on Seretide. Psychotic nightmares from day 2. Waking up very distressed. Shakes. fits. Saying 'Help me hlpe me please. I am going to die. Help me please. I am going to kill myself. Oh No. I died. Help me . Help me. There is

Been driving for 30 years -clean licence. Had a psychotic episode 5/6/11 whilst taking Champix and alcohol and ended up driving car - caught over limit banned,. Have no recollection of the events leading up to the driving or indeed the driving or of

CHAMPIX IS AWEFUL. IT CREATES PSYCHOTIC MOSTERS WHEN MIXED WITH ALCOHOL, AND IS RESPONSIBLE FOR HUNDREDS OF SUICIDES EVERY YEAR. THIS DRUG SHOULD BE BANNDED!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

DO NOT USE THIS DRUG!!!!!!!!!! if u search the internet it is linked to hundreds of suicides every year. i took it for 3 weeks, had some drinks one night and went into a fit that can only be described as a psychotic episode, that i do not even remebe

Do you think i have a Psychotic disorder

I am going on the anti-psychotic medication clozaril and i was wondering is it possible to go abroad to bangladesh someway and have my bloods done there so i can take clozaril there by means of post or if they supply it there

I think lyrica may be giving my husband psychotic episodes. i always thought he was borderline bipolar, but he has been on this for quite awhile and now seems out of his mind and has several other side effects also.

In the 1970s, I had some sort of psychotic episode, and ended up i a psychiatric hospital in Melbourne, Australia, and was given modecate injections, which made me like a different person. I was also given other drugs, and mostly was unable to cope w

It caused self destructive thoughts, fantasies of suicide, totally abnormal behavour, was told by family I was acting very negitivly, end result total mental breakdown,psychotic deppression ,super dry skin resulting inti hyper keratosis on

Psychotic Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: long-acting injectable risperidone;   Drug: long acting injectable risperidone
Outcome Measures: The primary end point will be change in PANSS Positive Subscale Score in the high dose group using a mixed model ANOVA;   change in PANSS; time to discontinuation for lack of efficacy and tolerability; change in cognitive domain scores; comparative incidence and time course of EPS, hyperprolactinemia, plasma lipids, weight gain, and other side effects between treatments
2 Unknown  Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
Condition: Schizophrenia
Interventions: Drug: Risperidone;   Drug: Paliperidone
Outcome Measure: Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal
3 Recruiting Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Conditions: Psychotic Disorders;   Schizophrenia;   Bipolar Disorder;   Depressive Disorder
Interventions: Drug: Aripiprazole, oral formulation;   Drug: Olanzapine, oral formulation;   Drug: Paliperidone, oral formulation;   Drug: Paliperidone, LAI;   Drug: Quetiapine, oral formulation;   Drug: Risperidone, oral formulation;   Drug: Risperidone, LAI
Outcome Measures: Aripiprazole concentration in venous and capillary plasma;   Paliperidone concentration in venous and capillary plasma;   Olanzapine concentration in venous and capillary plasma;   Quetiapine concentration in venous and capillary plasma;   Risperidone concentration in venous and capillary plasma;   Number of participants with an adverse event as a measure of safety
4 Recruiting A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
Condition: Methamphetamine Dependence
Interventions: Drug: paliperidone;   Drug: Risperidone
Outcome Measures: The severity of psychosis;   Clinical general status
5 Recruiting Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
Condition: Schizophrenia (Recent-onset)
Interventions: Drug: paliperidone palmitate;   Drug: risperidone
Outcome Measures: Exacerbation or relapse of psychotic symptoms;   Cognitive functioning based on Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery;   Role Functioning;   Cognitive performance on test battery (MCCB);   Insight (Awareness of Mental Disorder);   Retention in treatment;   Social functioning;   Emotional reactivity on psychophysiological measures
6 Recruiting Risperidone and Desipramine in Alcohol Use and Schizophrenia
Conditions: Schizophrenia;   Alcoholism;   Dual Diagnosis
Interventions: Drug: Risperidone + Desipramine;   Drug: Risperidone + Placebo
Outcome Measure: Timeline Followback
7 Recruiting Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Conditions: Attention Deficit/Hyperactivity Disorder;   Oppositional Defiant Disorder;   Conduct Disorder
Interventions: Drug: Methylphenidate;   Drug: Risperidone
Outcome Measures: Change from baseline of aggressive behaviors.;   Clinical Global Impression - Improvement scale (CGI-I) questionnaire;   ADHD-RS questionnaire;   Children's Depression Rating Scale (CDRS) questionnaire;   Young Mania Rating Scale (YMRS) questionnaire;   Children Sleep Habits Questionnaire (CSHQ);   Clinical Global Impression - Severity (CGI-S) questionnaire
8 Unknown  Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients
Condition: Schizophrenia
Interventions: Other: active Risperidone and active rTMS;   Other: active rTMS and sham Risperidone;   Other: sham rTMS and active Risperidone
Outcome Measures: PANSS;   Total AHRS score;   HAMD Score;   CGI;   fMRI
9 Not yet recruiting Bioavailability of LY03004 and Risperdal® Consta®
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: LY03004;   Drug: Risperdal® Consta®
Outcome Measures: Cmax, Tmax, for Relative bioavailability of LY03004 compared to Risperdal® Consta®;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   The change of the PANSS score for the Preliminary efficacy of LY03004
10 Unknown  Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
Condition: Schizophrenia
Interventions: Drug: Sertindole;   Drug: Risperidone
Outcome Measures: cognitive functioning;   Discontinuation due to all causes, symptomatology and adverse events.
11 Unknown  Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior
Condition: Autism
Intervention: Drug: Risperidone
Outcome Measure: Aberrant Behavior Checklist
12 Recruiting Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Risperidone
Outcome Measure: To identify phenotypic and genetic traits that predict response to aripiprazole and risperidone in Autistic Disorder
13 Recruiting A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Paliperidone extended-release;   Drug: Risperidone immediate-release
Outcome Measures: Change in category fluency score of cognitive function scale (Cognitive Abilities Screening Instrument, Chinese version [CASI C-2.0]) from baseline to Week 24;   Change from baseline to Week 24 in score of Modified Wisconsin Card Sorting Test (MWCST) short version;   Change from baseline in score of Continuous Performance Test (CPT);   Change from baseline in score of Personal and Social Performance (PSP) scale;   Change from baseline in score of Positive and Negative Syndrome Scale (PANSS);   Change from baseline in score of Clinical Global Impression-severity (CGI-S) scale;   Change from baseline in score of Medication Satisfaction Questionnaire (MSQ)
14 Unknown  Risperidone and Zotepine in the Treatment of Delirium
Condition: Delirium
Intervention: Drug: Risperidone and Zolpidem for delirium
Outcome Measures: Delirium rating scale;   MMSE, CGI, side effect profile, HRV
15 Recruiting Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Risperidone ISM
Outcome Measures: Peak Plasma Concentration (Cmax) for Active Moiety;   Trough Plasma Concentration (Cmin) for Active Moiety;   Area under the curve to the last quantified concentration (AUClast) and Area under the curve extrapolated to infinity (AUC∞) for Active Moiety;   Terminal rate constant (λz), Terminal half-life (t1/2) and Time to peak concentration (tmax) for Active Moiety;   Peak Plasma Concentration (Cmax) for Risperidone and 9OH-Risperidone Moieties;   Trough Plasma Concentration (Cmin) for Risperidone and 9OH-Risperidone Moieties;   Occurrence, nature, onset time, duration, intensity, action taken, outcome and relationship to study drug of AEs as a Measure of Safety;   Area under the curve to the last quantified concentration (AUClast) and Area under the curve extrapolated to infinity (AUC∞) for Risperidone and 9OH-Risperidone Moieties;   Terminal rate constant (λz), Terminal half-life (t1/2) and Time to peak concentration (tmax) for Risperidone and 9OH-Risperidone Moieties;   Area Under the Concentration-time Curve​ for To perform a descriptive comparison of the PK data between the gluteal and the deltoid muscle administration of the injectable ISM formulation
16 Recruiting Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Conditions: Delirium;   Agitation
Interventions: Drug: Risperidone;   Drug: Trazodone;   Drug: Placebo
Outcome Measures: The number of days patients are without delirium during the study period (delirium-free days);   Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU);   Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours;   The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day;   The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent;   The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication;   The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered;   The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered;   The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.;   The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days);   The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline);   The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   All-cause mortality and 28-day mortality
17 Unknown  Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
Conditions: Smoking Cessation;   Schizophrenia
Interventions: Drug: Tropisetron;   Drug: Placebo;   Drug: Risperidone
Outcome Measures: Cognitive deficits as assessed by tests measuring the MATRICS cognition domains;   Negative schizophrenic symptoms;   Reduction in side effects of risperidone;   Abnormality in P50 inhibition;   Nicotine use among all participants who smoke
18 Recruiting A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
Condition: Schizophrenia
Interventions: Drug: RO5545965;   Other: Placebo;   Drug: risperidone
Outcome Measures: Incidence of adverse events;   Health of the patients, assessed through a complete medical examination including physical examination, electrocardiogram (ECG) and vital signs.;   Pharmacokinetics: Plasma area under the concentration-time curve (AUC) of RO5545965;   Pharmacokinetics: Plasma area under the concentration-time curve (AUC) of risperidone
19 Not yet recruiting Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Paliperidone Palmitate;   Drug: Risperidone
Outcome Measures: Intracortical myelin;   Cognition;   Biomarker
20 Unknown  Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Risperdal Consta (drug);   Behavioral: Social Skills Training
Outcome Measures: Scores on an analogue measure of responsiveness to skills training.;   Scores on a measure of skills acquisition and performance pre-post a 3-month skills training group.;   Interview measures of social functioning.;   Neurocognitive functioning.;   Symptomatology.